New drug combo PrimeC shows promise in slowing ALS
NCT ID NCT05357950
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase IIb trial tested PrimeC, a combination of two common drugs (ciprofloxacin and celecoxib), in 69 people with ALS. Participants took PrimeC or a placebo for 6 months, followed by a 12-month open-label extension where everyone received PrimeC. The study measured safety, side effects, and how well the drug slowed disease progression using standard ALS rating scales and breathing tests.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PrimeC (a combination of ciprofloxacin and celecoxib)
What this could lead to
If successful, PrimeC could slow the progression of ALS and improve quality of life for patients.
What could go wrong
This is a small, early-phase (IIb) trial with only 69 participants. Results may not be conclusive, and the drug may not show significant benefit over placebo. Side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Citta della Salute e della Scienza di Torino
Torino, Italy
-
IRCCS Istituti clinici Maugeri
Milan, Italy
-
Lawson Health Research Institute
London, Ontario, Canada
-
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel